Starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027

What happened: Starling Oncology (STLN) reported Q3 2026 record revenue of $169.8 million, up 24% year-over-year, with adjusted EBITDA of $3.4 million, per CEO Daniel Virnich. Key numbers: Q3 2026 revenue $169.8M, up 24% YoY; adjusted EBITDA $3.4M; 2026 guidance $650M-$660M revenue and $4M-$6M adjusted EBITDA; 2027 target of 100% capitated revenue growth. Why it matters: Management issued 2026 revenue and adjusted EBITDA guidance and set a 2027 target for capitated revenue growth, framing the quarter as the second consecutive period of record results.

Starling Oncology (STLN) reported Q3 2026 record revenue of $169.8 million, up 24% year-over-year, with adjusted EBITDA of $3.4 million, per CEO Daniel Virnich.

Management issued 2026 revenue and adjusted EBITDA guidance and set a 2027 target for capitated revenue growth, framing the quarter as the second consecutive period of record results.